Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free XBIT Stock Alerts

XBiotech (XBIT) Financials

XBiotech logo
$2.29 0.00 (0.00%)
Closing price 07/16/2026 04:00 PM Eastern
Extended Trading
$2.30 +0.00 (+0.22%)
As of 07/16/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for XBiotech

Annual Income Statements for XBiotech

This table shows XBiotech's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -37 -53 -33 -21 669 -11 -17 -33 -25 -39 -46
Consolidated Net Income / (Loss)		 -37 -53 -33 -21 669 -11 -17 -33 -25 -39 -46
Net Income / (Loss) Continuing Operations		 -37 -53 -33 -21 669 -11 -17 -33 -25 -39 -46
Total Pre-Tax Income 		-37 -53 -33 -21 718 -13 -25 -34 -24 -39 -45
Total Operating Income		 -38 -53 -34 -21 -31 -18 -25 -34 -38 -42 -56
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 9.45 13 3.36 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 44 18 4.01 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 35 5.82 0.65 0.00 0.00 0.00
Total Operating Expenses		 38 53 34 21 31 28 38 38 38 42 56
Selling, General & Admin Expense		 6.20 10 7.64 5.27 7.14 18 9.39 6.31 4.66 4.71 8.30
Research & Development Expense		 31 42 26 16 24 9.53 28 32 33 38 47
Total Other Income / (Expense), net		 0.03 0.00 0.91 -0.14 750 5.45 -0.38 0.90 13 3.91 10
Interest & Investment Income		 0.00 0.05 0.35 0.40 0.56 2.46 0.47 3.82 10 9.01 5.59
Other Income / (Expense), net		 0.03 -0.05 0.56 -0.54 749 2.99 -0.84 -2.92 2.78 -5.10 4.79
Income Tax Expense		 - - 0.00 0.00 50 -1.61 -8.04 -0.69 0.24 -0.03 0.24
Basic Earnings per Share		 ($1.22) ($1.63) ($0.95) ($0.59) $17.17 ($0.36) ($0.58) ($1.08) ($0.81) ($1.26) ($1.49)
Weighted Average Basic Shares Outstanding		 30.80M 32.40M 34.88M 35.80M 38.95M 30.82M 30.04M 30.44M 30.44M 30.46M 30.49M
Weighted Average Diluted Shares Outstanding		 30.80M 32.40M 34.88M 35.80M 46.32M 30.82M 30.04M 30.44M 30.45M 30.49M 30.49M
Weighted Average Basic & Diluted Shares Outstanding		 30.80M 32.40M 34.88M 35.80M 28.85M 29.46M 30.44M 30.44M 30.45M 30.49M 30.49M

Quarterly Income Statements for XBiotech

This table shows XBiotech's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -7.36 -4.56 -10 -13 -5.02 -11 -11 -1.76 -6.01 -27 -5.51
Consolidated Net Income / (Loss)		 -7.36 -4.64 -10 -13 -5.02 -11 -11 -1.76 -6.01 -27 -5.51
Net Income / (Loss) Continuing Operations		 -7.36 -4.56 -10 -13 -5.02 -11 -11 -1.76 -6.01 -27 -5.51
Total Pre-Tax Income 		-7.06 -4.73 -9.98 -13 -5.01 -11 -11 -1.73 -5.91 -27 -5.46
Total Operating Income		 -8.52 -8.59 -11 -15 -7.90 -8.75 -14 -6.34 -6.05 -30 -6.27
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 8.52 8.59 11 15 7.90 8.75 14 6.34 6.05 30 6.27
Selling, General & Admin Expense		 0.97 0.78 1.03 1.98 0.78 0.93 1.93 1.00 0.97 4.40 1.07
Research & Development Expense		 7.55 7.81 9.83 13 7.13 7.82 12 5.34 5.08 25 5.21
Total Other Income / (Expense), net		 1.46 3.85 0.88 1.94 2.90 -1.80 2.70 4.61 0.14 2.94 0.82
Interest & Investment Income		 2.53 2.60 2.46 2.49 2.17 1.89 1.42 1.53 1.43 1.22 0.91
Other Income / (Expense), net		 -1.07 1.25 -1.58 -0.55 0.73 -3.69 1.28 3.08 -1.29 1.72 -0.10
Income Tax Expense		 0.31 -0.17 0.03 -0.03 0.01 -0.04 0.03 0.03 0.10 0.08 0.05
Basic Earnings per Share		 ($0.24) ($0.15) ($0.33) ($0.43) ($0.16) ($0.34) ($0.36) ($0.06) ($0.20) ($0.87) ($0.18)
Weighted Average Basic Shares Outstanding		 30.44M 30.44M 30.44M 30.46M 30.47M 30.46M 30.49M 30.49M 30.49M 30.49M 30.49M
Weighted Average Diluted Shares Outstanding		 30.44M 30.45M 30.46M 30.46M 30.48M 30.49M 30.49M 30.49M 30.49M 30.49M 30.49M
Weighted Average Basic & Diluted Shares Outstanding		 30.44M 30.45M 30.46M 30.46M 30.48M 30.49M 30.49M 30.49M 30.49M 30.49M 30.49M

Annual Cash Flow Statements for XBiotech

This table details how cash moves in and out of XBiotech's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 34 -57 -2.56 -16 699 -477 -0.38 -15 -81 -27 -47
Net Cash From Operating Activities		 -33 -46 -34 -17 -18 -65 69 -15 -19 -31 -40
Net Cash From Continuing Operating Activities		 -33 -46 -34 -17 -18 -65 69 -15 -19 -31 -40
Net Income / (Loss) Continuing Operations		 -37 -53 -33 -21 669 -11 -17 -33 -25 -39 -46
Consolidated Net Income / (Loss)		 -37 -53 -33 -21 669 -11 -17 -33 -25 -39 -46
Depreciation Expense		 0.70 0.70 1.48 2.43 2.36 2.24 2.65 2.61 1.74 1.75 1.69
Non-Cash Adjustments To Reconcile Net Income		 4.25 5.57 2.15 1.66 -747 13 80 7.86 1.37 7.28 0.29
Changes in Operating Assets and Liabilities, net		 -0.77 0.48 -4.13 0.51 57 -69 4.69 7.60 2.72 -1.46 3.65
Net Cash From Investing Activities		 -10 -14 -1.41 -0.12 675 -3.73 -3.53 -64 61 -1.30 -0.29
Net Cash From Continuing Investing Activities		 -10 -14 -1.41 -0.12 675 -3.73 -3.53 -0.59 -62 -1.30 -0.29
Purchase of Property, Plant & Equipment		 -2.32 -4.75 -1.41 -0.12 -0.20 -3.73 -3.53 -0.59 -0.36 -1.30 -0.29
Net Cash From Financing Activities		 77 2.94 33 0.20 42 -410 -67 0.00 -0.01 10 -10
Net Cash From Continuing Financing Activities		 77 2.94 33 0.20 42 -410 -67 0.00 -0.01 10 -10
Issuance of Debt		 - - - - - - - - 0.00 10 -10
Issuance of Common Equity		 77 2.94 33 0.20 3.73 10 8.00 0.00 0.01 0.20 0.00
Other Net Changes in Cash		 - - - - 0.15 1.37 0.71 - - -5.53 3.33
Cash Interest Paid		 - - - - - - - - 0.00 0.40 0.49
Cash Income Taxes Paid		 - - - 0.00 0.00 54 - - 0.14 0.09 -0.08

Quarterly Cash Flow Statements for XBiotech

This table details how cash moves in and out of XBiotech's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 59 -126 1.02 -13 -5.41 -10 -17 -2.96 -5.57 -22 -10
Net Cash From Operating Activities		 -1.49 -3.43 -7.20 -11 -5.85 -6.54 -6.72 -5.99 -4.26 -23 -8.97
Net Cash From Continuing Operating Activities		 -1.49 -3.43 -7.20 -11 -5.85 -6.54 -6.72 -5.99 -4.26 -23 -8.97
Net Income / (Loss) Continuing Operations		 -7.36 -4.64 -10 -13 -5.02 -11 -11 -1.76 -6.01 -27 -5.51
Consolidated Net Income / (Loss)		 -7.36 -4.64 -10 -13 -5.02 -11 -11 -1.76 -6.01 -27 -5.51
Depreciation Expense		 0.43 0.43 0.43 0.44 0.44 0.44 0.44 0.44 0.43 0.38 0.33
Non-Cash Adjustments To Reconcile Net Income		 2.02 -0.56 1.96 0.93 -0.34 4.73 3.05 -2.97 1.23 -1.01 1.30
Changes in Operating Assets and Liabilities, net		 3.43 1.33 0.41 0.26 -0.93 -1.20 0.68 -1.70 0.10 4.57 -5.10
Net Cash From Investing Activities		 62 -0.12 -0.26 -0.63 -0.34 -0.08 -0.09 -0.05 -0.11 -0.03 0.01
Net Cash From Continuing Investing Activities		 62 -124 -0.26 -0.63 -0.34 -0.08 -0.09 -0.05 -0.11 -0.03 0.00
Purchase of Property, Plant & Equipment		 -0.03 -0.12 -0.26 -0.63 -0.34 -0.08 -0.09 -0.05 -0.11 -0.03 0.00
Net Cash From Financing Activities		 0.01 - 10 0.05 0.06 0.28 -10 - - - 0.00
Net Cash From Continuing Financing Activities		 0.01 - 10 0.05 0.06 0.28 -10 - - - 0.00
Issuance of Debt		 - - 10 - - 0.25 -10 - - - 0.00
Other Net Changes in Cash		 - - - - - - 0.28 - - - -1.13
Cash Interest Paid		 - - 0.40 -0.40 0.40 - 0.49 - - - 0.00

Annual Balance Sheets for XBiotech

This table presents XBiotech's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 109 67 63 44 817 354 275 246 227 199 150
Total Current Assets		 93 37 33 17 716 326 247 220 202 175 127
Cash & Equivalents		 91 34 32 16 715 237 237 157 200 173 126
Note & Lease Receivable		 - - - - - - 0.00 1.22 0.86 0.70 0.36
Prepaid Expenses		 1.99 2.61 1.56 1.19 1.67 0.58 0.93 0.60 0.76 1.03 1.04
Plant, Property, & Equipment, net		 5.95 10 30 27 25 27 28 26 25 25 23
Total Noncurrent Assets		 10 20 0.00 0.00 75 0.53 0.00 0.00 0.00 0.00 0.00
Total Liabilities & Shareholders' Equity		 109 67 63 44 817 354 275 246 227 199 150
Total Liabilities		 6.31 7.99 2.81 2.95 61 5.11 5.79 5.70 7.77 17 9.73
Total Current Liabilities		 6.29 7.96 2.79 2.94 60 3.98 3.45 4.07 6.10 15 7.93
Accounts Payable		 4.83 4.43 1.73 1.65 2.15 2.49 2.07 2.41 2.52 2.22 1.54
Accrued Expenses		 1.47 3.53 1.06 1.29 4.18 1.35 1.37 1.60 3.50 2.63 6.32
Current Deferred & Payable Income Tax Liabilities		 - - - - 49 0.14 0.01 0.06 0.08 0.00 0.08
Total Noncurrent Liabilities		 0.02 0.02 0.02 0.00 1.06 1.12 2.34 1.64 1.67 1.72 1.80
Noncurrent Deferred Revenue		 0.02 0.02 0.02 0.00 1.06 1.12 1.47 1.58 1.67 1.72 1.80
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - - 0.87 0.06 - 0.00 0.01
Total Equity & Noncontrolling Interests		 103 59 60 41 756 349 269 240 219 182 140
Total Preferred & Common Equity		 103 59 60 41 756 349 269 240 219 182 140
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 103 59 60 41 756 349 269 240 219 182 140
Common Stock		 234 242 277 279 325 250 262 267 271 273 277
Retained Earnings		 -131 -183 -217 -238 431 98 5.15 -28 -52 -91 -136

Quarterly Balance Sheets for XBiotech

This table presents XBiotech's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 230 228 216 210 182 179 172 140
Total Current Assets		 204 203 191 185 158 155 149 117
Cash & Equivalents		 202 201 189 183 156 153 147 115
Note & Lease Receivable		 - - - - - - - 0.30
Prepaid Expenses		 0.88 1.07 1.12 1.05 1.15 1.31 1.06 1.29
Plant, Property, & Equipment, net		 25 25 25 25 24 24 23 23
Total Noncurrent Assets		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Liabilities & Shareholders' Equity		 230 228 216 210 182 179 172 140
Total Liabilities		 6.94 19 19 18 7.15 5.62 5.34 4.82
Total Current Liabilities		 5.29 17 17 16 5.41 3.86 3.57 3.00
Accounts Payable		 1.47 2.61 1.70 1.51 1.10 1.43 1.04 0.86
Accrued Expenses		 3.67 4.19 5.35 4.49 4.30 2.41 2.42 2.04
Current Deferred & Payable Income Tax Liabilities		 0.16 0.08 0.08 0.00 0.01 0.02 0.10 0.11
Total Noncurrent Liabilities		 1.65 1.69 1.72 1.74 1.74 1.76 1.78 1.82
Noncurrent Deferred Revenue		 1.65 1.69 1.72 1.74 1.74 1.76 1.78 1.82
Noncurrent Deferred & Payable Income Tax Liabilities		 0.00 - - - - - - 0.01
Total Equity & Noncontrolling Interests		 223 209 197 192 175 173 167 135
Total Preferred & Common Equity		 223 209 197 192 175 173 167 135
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 223 209 197 192 175 173 167 135
Common Stock		 270 272 272 272 276 277 277 277
Retained Earnings		 -48 -62 -75 -80 -102 -103 -109 -142

Annual Metrics And Ratios for XBiotech

This table displays calculated financial ratios and metrics derived from XBiotech's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 32,184,465.00 32,463,692.00 35,437,772.00 35,819,772.00 41,086,669.00 29,260,613.00 30,399,309.00 30,439,277.00 30,436,964.00 30,483,481.00 30,487,731.00
DEI Adjusted Shares Outstanding		 32,184,465.00 32,463,692.00 35,437,772.00 35,819,772.00 41,086,669.00 29,260,613.00 30,399,309.00 30,439,277.00 30,436,964.00 30,483,481.00 30,487,731.00
DEI Earnings Per Adjusted Shares Outstanding		 -1.16 -1.63 -0.94 -0.59 16.27 -0.38 -0.57 -1.08 -0.81 -1.26 -1.49
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -58.19% -78.20% -100.00% 0.00% 0.00%
EBITDA Growth		 -74.65% -41.67% 38.56% 40.33% 3,869.96% -101.81% -78.44% -49.49% 5.19% -38.90% -7.39%
EBIT Growth		 -72.53% -40.89% 36.56% 35.72% 3,433.13% -102.13% -69.63% -44.30% 7.16% -36.95% -7.00%
NOPAT Growth		 -72.24% -40.66% 35.45% 38.36% -97.79% 55.99% -37.24% -37.51% -8.76% -13.23% -31.11%
Net Income Growth		 -72.54% -40.76% 37.17% 36.24% 3,263.16% -101.68% -55.19% -88.93% 25.36% -56.90% -18.19%
EPS Growth		 -35.56% -33.61% 41.72% 37.89% 2,547.46% -102.49% -61.11% -86.21% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 -184.68% -38.15% 26.87% 50.85% -10.48% -256.59% 206.59% -121.35% -26.32% -65.36% -28.93%
Free Cash Flow Firm Growth		 -115.72% -35.89% 44.65% 56.80% -274.92% -86.46% 173.85% -123.92% -51.08% -38.78% -10.37%
Invested Capital Growth		 605.41% 106.18% 14.77% -9.93% 60.46% 171.15% -70.88% -29.25% -17.89% 5.41% -25.41%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 13.61% -4.01% -51.16% -100.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -17.87% -9.62% 22.98% 5.44% 3,363.04% -101.80% -30.51% 6.50% -7.32% -12.52% -46.65%
EBIT Q/Q Growth		 -17.33% -9.45% 21.41% 4.76% 3,031.95% -102.11% -27.29% 6.68% -6.89% -12.02% -44.17%
NOPAT Q/Q Growth		 -17.85% -9.03% 20.78% 6.25% -72.80% 48.59% -9.96% -2.89% -1.15% -0.38% -60.56%
Net Income Q/Q Growth		 -17.33% -9.34% 21.63% 5.11% 2,888.63% -101.66% -36.22% 9.03% -6.19% -17.98% -56.19%
EPS Q/Q Growth		 -10.91% -8.67% 25.20% 1.67% 2,321.54% -102.47% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -27.79% -4.80% 15.12% 9.28% 6.98% 4.90% -1.93% -10.47% -1.46% -11.15% -69.81%
Free Cash Flow Firm Q/Q Growth		 0.00% 1.27% 17.76% 12.61% -196.52% 23.34% 8.59% -13.74% -2.01% -9.24% -35.79%
Invested Capital Q/Q Growth		 42.90% -0.39% 0.79% -1.97% 68.99% 3.31% -8.16% -7.22% -8.04% 4.44% -24.93%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 21.48% 68.36% 83.77% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -29.65% -126.55% -867.76% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -41.54% -136.36% -860.10% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -34.74% -140.94% -932.94% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -25.50% -94.67% -820.45% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 93.07% 87.48% 68.40% 97.95% 101.00% 99.92% 100.52%
Interest Burden Percent		 100.00% 99.91% 98.94% 98.14% 100.08% 83.93% 98.20% 89.78% 70.00% 81.07% 89.01%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 6.93% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -16.80% -24.44% -87.28% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% -17.13% -24.50% -83.42% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 14.77% 18.81% 74.37% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -46.25% -65.09% -55.61% -41.63% 167.78% -2.03% -5.64% -12.91% -10.69% -19.21% -28.23%
Cash Return on Invested Capital (CROIC)		 -533.65% -270.42% -103.49% -44.01% -133.70% -109.03% 85.35% -53.01% -106.14% -159.05% -195.94%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -2.61% -8.24% -14.35% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -1.92% -5.54% -12.62% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -46.25% -65.09% -55.61% -41.63% 167.78% -2.03% -5.64% -12.91% -10.69% -19.21% -28.23%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -26 -37 -24 -15 -29 -13 -18 -24 -26 -30 -39
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -29.08% -95.45% -602.07% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -15.13% -25.25% -28.17% -27.07% 191.04% 0.33% 0.06% -3.85% 0.81% -4.86% -4.56%
Return On Investment Capital (ROIC_SIMPLE)		 -25.48% -62.53% -39.63% -35.50% -3.85% -3.67% -6.52% -10.04% -12.00% -15.44% -27.77%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 78.52% 31.64% 16.23% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 41.36% 51.04% 157.23% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 21.65% 153.68% 786.63% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 63.02% 204.72% 943.87% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -37 -53 -34 -22 718 -15 -26 -37 -35 -48 -51
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -37 -52 -32 -19 720 -13 -23 -35 -33 -46 -49
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.00 4.92 2.05 3.88 0.90 1.16 1.26 0.44 0.56 0.66 0.52
Price to Tangible Book Value (P/TBV)		 3.00 4.92 2.05 3.88 0.90 1.16 1.26 0.44 0.56 0.66 0.52
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 9.20 18.39 26.64 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 1.01 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 18.86% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 98.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 18.18 10.35 3.23 5.67 0.00 1.50 3.13 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 3.80 5.51 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 1.46 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 1.65 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.06 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.92 -0.77 -0.55 -0.47 -0.92 -0.86 -0.77 -0.89 -0.91 -0.90 -0.89
Leverage Ratio		 1.06 1.09 1.09 1.06 1.08 1.06 1.02 1.02 1.03 1.06 1.08
Compound Leverage Factor		 1.06 1.09 1.08 1.04 1.08 0.89 1.00 0.92 0.72 0.86 0.96
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 5.32% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 5.32% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 94.68% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.22 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.54 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.34 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.46 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 27.56 15.90 20.36 24.02 11.24 49.03 35.89 11.65 9.61 3.83 3.05
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 14.79 4.64 11.94 5.78 11.90 81.80 71.49 54.07 33.07 11.56 16.01
Quick Ratio		 14.47 4.31 11.38 5.37 11.87 60.61 68.63 53.79 32.93 11.48 15.88
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -37 -50 -27 -12 -45 -83 61 -15 -22 -31 -34
Operating Cash Flow to CapEx		 -1,434.45% -969.55% -2,394.95% -13,554.92% 0.00% -1,748.03% 1,970.07% -2,534.02% -5,172.65% -2,374.46% -13,813.15%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.08 0.06 0.02 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 1.68 0.66 0.15 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 14.89 2.55 0.29 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 24.51 142.99 1,255.07 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 -24.51 -142.99 -1,255.07 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 12 25 28 26 41 111 32 23 19 20 15
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.58 0.26 0.15 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 10 13 3.65 -2.82 15 70 -79 -9.48 -4.10 1.02 -5.04
Enterprise Value (EV)		 218 256 92 145 -37 167 101 -111 -78 -42 -53
Market Capitalization		 309 290 123 161 678 405 338 107 122 120 73
Book Value per Share		 $3.20 $1.82 $1.70 $1.16 $18.39 $11.92 $8.86 $7.90 $7.19 $5.98 $4.60
Tangible Book Value per Share		 $3.20 $1.82 $1.70 $1.16 $18.39 $11.92 $8.86 $7.90 $7.19 $5.98 $4.60
Total Capital		 103 59 60 41 756 349 269 240 219 193 140
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -91 -34 -32 -16 -715 -237 -237 -217 -200 -162 -126
Capital Expenditures (CapEx)		 2.32 4.75 1.41 0.12 -675 3.73 3.53 0.59 0.36 1.30 0.29
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.30 -5.36 -1.23 -1.75 -59 85 6.43 -1.70 -4.41 -2.97 -6.53
Debt-free Net Working Capital (DFNWC)		 87 29 31 14 656 322 243 216 196 170 119
Net Working Capital (NWC)		 87 29 31 14 656 322 243 216 196 159 119
Net Nonoperating Expense (NNE)		 11 16 9.31 6.44 -698 -1.57 -0.14 8.76 -1.70 8.80 6.56
Net Nonoperating Obligations (NNO)		 -91 -34 -32 -16 -715 -237 -237 -217 -200 -162 -126
Total Depreciation and Amortization (D&A)		 0.70 0.70 1.48 2.43 2.36 2.24 2.65 2.61 1.74 1.75 1.69
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 192.12% 34.98% -42.42% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 731.62% 1,323.35% 5,380.97% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 731.62% 1,323.35% 5,380.97% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.22) ($1.63) ($0.95) ($0.59) $17.17 ($0.36) ($0.58) ($1.08) ($0.81) ($1.26) ($1.49)
Adjusted Weighted Average Basic Shares Outstanding		 32.29M 35.15M 35.44M 36.05M 38.95M 30.82M 30.04M 30.44M 30.44M 30.46M 30.49M
Adjusted Diluted Earnings per Share		 ($1.22) ($1.63) ($0.95) ($0.59) $14.44 ($0.36) ($0.58) ($1.08) ($0.81) $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 32.29M 35.15M 35.44M 36.05M 46.32M 30.82M 30.04M 30.44M 30.44M 30.49M 30.49M
Adjusted Basic & Diluted Earnings per Share		 ($1.22) ($1.63) ($0.95) ($0.59) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 30.80M 32.40M 34.88M 35.80M 28.85M 29.46M 30.44M 30.44M 30.45M 30.49M 30.49M
Normalized Net Operating Profit after Tax (NOPAT)		 -26 -37 -24 -15 -29 -13 -18 -24 -26 -30 -39
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -29.08% -95.45% -602.07% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -29.15% -138.40% -837.61% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -430.71% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% -5.69% -3,742.98% -430.71% 0.00% -0.06% 0.00% 0.00%

Quarterly Metrics And Ratios for XBiotech

This table displays calculated financial ratios and metrics derived from XBiotech's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 30,435,714.00 30,436,964.00 30,450,881.00 30,457,531.00 30,463,156.00 30,483,481.00 30,487,731.00 30,487,731.00 30,487,731.00 30,487,731.00 30,487,731.00
DEI Adjusted Shares Outstanding		 30,435,714.00 30,436,964.00 30,450,881.00 30,457,531.00 30,463,156.00 30,483,481.00 30,487,731.00 30,487,731.00 30,487,731.00 30,487,731.00 30,487,731.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.24 -0.15 -0.33 -0.43 -0.16 -0.34 -0.36 -0.06 -0.20 -0.88 -0.18
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 13.09% -48.32% -93.94% -40.39% 26.44% -73.87% 1.45% 81.31% -2.57% -130.43% 48.96%
EBIT Growth		 14.92% -43.95% -87.50% -38.82% 25.17% -69.57% 1.32% 79.01% -2.24% -125.34% 48.09%
NOPAT Growth		 -33.35% -5.21% -51.90% -12.88% 7.23% -1.87% -24.85% 57.66% 23.49% -240.10% 53.70%
Net Income Growth		 41.82% -44.71% -162.11% -48.78% 31.90% -126.71% -8.82% 86.50% -19.80% -155.92% 49.42%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 -29.30% -8.50% -49.79% -26.44% -293.07% -90.50% 6.69% 47.35% 27.13% -250.95% -33.47%
Free Cash Flow Firm Growth		 -128.25% -150.73% -135.49% -21.97% -135.74% -273.93% -530.68% -46.73% -21.84% -121.02% 48.97%
Invested Capital Growth		 -17.16% -17.89% -24.76% -25.20% -7.19% 5.41% 3.15% 10.76% 3.77% -25.41% 3.94%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 14.82% 24.58% -73.88% -25.68% 55.37% -78.26% 1.44% 76.17% -144.98% -300.46% 78.17%
EBIT Q/Q Growth		 14.27% 23.45% -69.48% -24.81% 53.79% -73.47% 1.37% 73.45% -125.08% -282.30% 77.28%
NOPAT Q/Q Growth		 35.74% -0.79% -26.39% -37.90% 47.19% -10.68% -54.89% 53.24% 4.56% -392.01% 78.91%
Net Income Q/Q Growth		 15.76% 37.06% -115.79% -30.03% 61.44% -109.53% -3.58% 83.87% -242.14% -347.60% 79.53%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 83.47% -130.87% -109.79% -57.96% 48.62% -11.89% -2.75% 10.88% 28.89% -438.91% 60.92%
Free Cash Flow Firm Q/Q Growth		 51.74% -10.85% 16.48% -173.04% 6.74% -75.82% -40.86% 36.48% 22.55% -218.95% 67.48%
Invested Capital Q/Q Growth		 -15.74% -8.04% -3.09% -0.38% 4.55% 4.44% -5.17% 6.96% -2.05% -24.93% 32.16%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 104.37% 97.93% 100.25% 99.81% 100.18% 99.61% 100.27% 101.62% 101.73% 100.28% 100.90%
Interest Burden Percent		 73.62% 64.51% 80.23% 83.96% 69.80% 84.79% 88.46% 53.04% 80.54% 95.66% 85.65%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -10.69% -13.78% -16.44% -15.75% -19.21% -20.53% -15.23% -16.23% -28.23% -25.93%
Cash Return on Invested Capital (CROIC)		 -96.15% -106.14% -107.57% -112.70% -142.64% -159.05% -173.75% -143.78% -129.13% -195.94% -180.48%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% -10.69% -13.78% -16.44% -15.75% -19.21% -20.53% -15.23% -16.23% -28.23% -25.93%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -5.96 -6.01 -7.60 -10 -5.53 -6.12 -9.49 -4.44 -4.23 -21 -4.39
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -0.66% 0.66% -1.19% -1.32% 0.28% -2.42% -0.81% 1.62% -1.11% -4.21% -0.82%
Return On Investment Capital (ROIC_SIMPLE)		 -2.68% -2.75% -3.46% -5.07% -2.74% -3.18% -5.43% -2.56% -2.53% -14.84% -3.25%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -9.59 -7.34 -12 -16 -7.17 -12 -12 -3.26 -7.33 -28 -6.37
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.15 -6.90 -12 -15 -6.73 -12 -12 -2.82 -6.91 -28 -6.04
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.56 0.56 1.18 0.80 1.23 0.66 0.57 0.52 0.49 0.52 0.53
Price to Tangible Book Value (P/TBV)		 0.56 0.56 1.18 0.80 1.23 0.66 0.57 0.52 0.49 0.52 0.53
Price to Revenue (P/Rev)		 417.98 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 3.10 0.00 3.28 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.05 0.05 0.05 0.06 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.90 -0.91 -0.90 -0.90 -0.90 -0.90 -0.90 -0.90 -0.89 -0.89 -0.88
Leverage Ratio		 1.03 1.03 1.05 1.06 1.06 1.06 1.07 1.07 1.06 1.08 1.04
Compound Leverage Factor		 0.76 0.66 0.85 0.89 0.74 0.90 0.94 0.57 0.86 1.04 0.89
Debt to Total Capital		 0.00% 0.00% 4.56% 4.84% 4.95% 5.32% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 4.56% 4.84% 4.95% 5.32% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 95.44% 95.16% 95.05% 94.68% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 -0.26 -0.23 -0.25 -0.22 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 4.92 4.14 4.25 3.54 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 -0.35 -0.33 -0.34 -0.34 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 6.62 5.94 5.85 5.46 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 11.45 10.01 8.41 5.22 8.28 4.41 8.29 9.81 9.09 3.56 8.33
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 38.61 33.07 12.03 11.13 11.57 11.56 29.15 40.16 41.78 16.01 39.03
Quick Ratio		 38.36 32.93 11.96 11.05 11.50 11.48 28.91 39.78 41.46 15.88 38.60
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.72 -1.91 -1.60 -4.36 -4.06 -7.14 -10 -6.39 -4.95 -16 -5.13
Operating Cash Flow to CapEx		 -4,506.06% -2,985.22% -2,824.31% -1,814.35% -1,699.13% -8,384.62% -7,148.94% -11,743.14% -3,871.82% -67,505.88% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 1,466.69 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 32,439.38 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 -30,972.68 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 20 19 18 18 19 20 19 20 20 15 20
Invested Capital Turnover		 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -4.24 -4.10 -6.00 -6.12 -1.47 1.02 0.58 1.96 0.72 -5.04 0.74
Enterprise Value (EV)		 -77 -78 57 -22 62 -42 -57 -62 -66 -53 -44
Market Capitalization		 125 122 248 157 235 120 99 91 81 73 72
Book Value per Share		 $7.32 $7.19 $6.87 $6.46 $6.31 $5.98 $5.73 $5.68 $5.48 $4.60 $4.43
Tangible Book Value per Share		 $7.32 $7.19 $6.87 $6.46 $6.31 $5.98 $5.73 $5.68 $5.48 $4.60 $4.43
Total Capital		 223 219 219 207 202 193 175 173 167 140 135
Total Debt		 0.00 0.00 10 10 10 10 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -202 -200 -191 -179 -173 -162 -156 -153 -147 -126 -115
Capital Expenditures (CapEx)		 0.03 0.12 0.26 0.63 0.34 0.08 0.09 0.05 0.11 0.03 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.08 -4.41 -4.87 -5.03 -4.08 -2.97 -3.62 -1.91 -1.98 -6.53 -1.41
Debt-free Net Working Capital (DFNWC)		 199 196 196 184 179 170 152 151 145 119 114
Net Working Capital (NWC)		 199 196 186 174 169 159 152 151 145 119 114
Net Nonoperating Expense (NNE)		 1.40 -1.38 2.40 2.53 -0.52 4.38 1.40 -2.68 1.78 6.07 1.11
Net Nonoperating Obligations (NNO)		 -202 -200 -191 -179 -173 -162 -156 -153 -147 -126 -115
Total Depreciation and Amortization (D&A)		 0.43 0.43 0.43 0.44 0.44 0.44 0.44 0.44 0.43 0.38 0.33
Debt-free, Cash-free Net Working Capital to Revenue		 -1,027.67% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 66,369.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 66,369.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.24) ($0.15) ($0.33) ($0.43) ($0.16) ($0.34) ($0.36) ($0.06) ($0.20) ($0.87) ($0.18)
Adjusted Weighted Average Basic Shares Outstanding		 30.44M 30.44M 30.44M 30.46M 30.47M 30.46M 30.49M 30.49M 30.49M 30.49M 30.49M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 30.44M 30.45M 30.46M 30.46M 30.48M 30.49M 30.49M 30.49M 30.49M 30.49M 30.49M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 30.44M 30.45M 30.46M 30.46M 30.48M 30.49M 30.49M 30.49M 30.49M 30.49M 30.49M
Normalized Net Operating Profit after Tax (NOPAT)		 -5.96 -6.01 -7.60 -10 -5.53 -6.12 -9.49 -4.44 -4.23 -21 -4.39
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.06% -0.06% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

XBiotech (NASDAQ: XBIT) remains a cash-rich biotech, but its recent quarterly results show a business still producing no revenue and burning cash at a meaningful rate. Over the last four years, the company has consistently posted operating losses, and Q1 2026 continued that pattern with $0 in revenue and a net loss of $5.5 million. The main bright spot is the balance sheet: XBiotech still had $115.5 million in cash and equivalents at the end of Q1 2026, which gives it flexibility to keep funding operations. However, cash has declined materially from prior periods, and the company is still relying on its existing capital base rather than operating profits.

Recent trend snapshot: quarterly operating losses have generally improved from the much larger losses seen in 2024 and late 2025, but that improvement has come alongside continued lack of sales and ongoing cash usage. In other words, losses are smaller than they were, but the core business has yet to generate revenue.

  • Strong cash position: XBiotech ended Q1 2026 with $115.5 million in cash and equivalents, giving it a solid runway for ongoing clinical and corporate expenses.
  • Losses improved year over year: Q1 2026 net loss of $5.5 million was smaller than the $10.0 million loss in Q1 2024 and the $10.9 million loss in Q1 2025.
  • Operating expenses were much lower than late 2025: Q1 2026 operating expenses were $6.27 million, down sharply from $29.75 million in Q4 2025.
  • Low debt profile in the latest quarter: Q1 2026 showed no short-term debt on the balance sheet, reducing near-term financing risk compared with some earlier periods.
  • Interest income helped offset losses: XBiotech earned $914,000 in interest and investment income in Q1 2026, which partially cushioned the operating deficit.
  • Balance sheet remains equity-heavy: Total equity of $135.0 million still exceeded total liabilities of $4.8 million in Q1 2026.
  • Revenue remains absent: the company reported $0 revenue in every quarter shown, so the story is still about research spending and cash preservation rather than growth.
  • Cash burn continues: operating cash flow was negative $9.0 million in Q1 2026, indicating the company is still consuming cash to fund operations.
  • Cash balance is trending down: cash and equivalents fell from $147.4 million in Q3 2025 to $115.5 million in Q1 2026.
  • Shareholders’ equity has weakened versus a year ago: total equity declined from $192.1 million in Q3 2024 to $135.0 million in Q1 2026, reflecting accumulated losses and balance sheet changes.

Bottom line: XBiotech’s financial position is still supported by a sizeable cash reserve, but the company has not yet shown a path to revenue generation. For retail investors, the key question remains whether its pipeline can eventually convert that cash into meaningful clinical or commercial value before the balance sheet is further depleted.

07/17/26 02:46 AM ETAI Generated. May Contain Errors.

XBiotech Financials - Frequently Asked Questions

According to the most recent income statement we have on file, XBiotech's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

XBiotech's net income appears to be on a downward trend, with a most recent value of -$45.54 million in 2025, rising from -$37.48 million in 2015. The previous period was -$38.53 million in 2024. See XBiotech's forecast for analyst expectations on what's next for the company.

XBiotech's total operating income in 2025 was -$55.69 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $55.69 million

Over the last 10 years, XBiotech's total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

XBiotech's total liabilities were at $9.73 million at the end of 2025, a 42.2% decrease from 2024, and a 54.3% increase since 2015.

In the past 10 years, XBiotech's cash and equivalents has ranged from $15.82 million in 2018 to $714.59 million in 2019, and is currently $125.55 million as of their latest financial filing in 2025.

Over the last 10 years, XBiotech's book value per share changed from 3.20 in 2015 to 4.60 in 2025, a change of 43.8%.


Related Companies

Financial statements for NASDAQ:XBIT last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel